Already have an account? Log in

Developing a nanotechnology-enabled glaucoma device

VisiPlate is designed to treat open-angle glaucoma

VisiPlate is an investigational implant designed to lower intraocular pressure in patients with open-angle glaucoma

A next-generation aqueous shunt

Multichannel – VisiPlate is designed to lower eye pressure through a network of microchannels that control aqueous drainage from the anterior chamber.

A single, finger upright against a white home background with a VisiPlate on top.

A next generation aqueous shunt

Ultrathin – VisiPlate is several times thinner than a human hair. VisiPlate leverages an ultrathin material with the goal of achieving greater patient comfort and aesthetics.

A next-generation aqueous shunt

Innovative Composition – VisiPlate is composed of alumina and Parylene-C with the goal of minimizing foreign body response and reducing the risk of scarring.

Building at the cutting edge

Avisi leverages MEMS (Micro-Electro-Mechanical Systems) manufacturing and utilizes high-performance equipment and advanced micro-fabrication manufacturing techniques. This development of small and advanced medical devices is intended to be at the forefront of minimally-invasive treatments.

Avisi’s proprietary material technology features an ultrathin, freestanding material, invented at the University of Pennsylvania.

Avisi’s scientific advisors hail from world-class institutions and bring together a diverse array of expertise. Drawing from leading universities, renowned research centers, and top-tier industry leaders, their experience helps guide Avisi.

Glaucoma is the "silent thief of sight"

Glaucoma is the leading cause of irreversible blindness. It was estimated to affect 4 million in the US and 103 million people world-wide. The overall prevalence within the US is 2.1% and 3.54% globally. It is estimated that 3.36 million people 40 years and older in the US have open-angle glaucoma. This disease is on the rise and expected to reach 111.8 million globally by 2040.

Glaucoma is a group of eye diseases that damage the optic nerve and result in vision loss. The two most common types are primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). 90% of US glaucoma patients have POAG. There are typically no early warning signs or symptoms for POAG which is why it is known as the “silent thief of sight.” Consequently, routine eye exams are critical to diagnosis. No cure for glaucoma has been discovered yet and the only clinically proven way to modify disease progression is to lower the pressure inside the eye. Current treatments cannot reverse vision loss but are designed to slow disease progression, thereby preventing further vision loss.

Everyone is at risk for developing glaucoma, but certain groups have a higher risk. All people over the age of 60 are 6 times more likely to develop a type of glaucoma. Those with diabetes are twice as more likely to develop a type of glaucoma. Prevalence also varies with race. People of African-Caribbean and African American descent over the age of 40 are 8 times more likely to develop POAG.

Today, the national economic impact of glaucoma takes up the majority of $5.8 billion spent on treatment and management of optic nerve disorders. Ten million doctor visits occur each year for glaucoma resulting in $2.5 billion in annual healthcare costs. The burden of these costs on the US healthcare system is expected to significantly rise as the number of patients increases. Only 50% of people with glaucoma are diagnosed. The other 50% are unaware of their disease. Additionally, it is projected that the number of people affected by glaucoma will increase two folds by 2050.

Avisi in the news

Ophthalmology Times Cutting-Edge Advancements Avisi Technologies FDA, IDE

Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA

Key Takeaways VisiPlate’s IDE approval allows clinical studies in the US, focusing on safety and effectiveness data collection for the novel glaucoma treatment device. The device’s unique metamaterial and multichannel design aim to reduce IOP and minimize blockage risks, offering potential advantages over current surgical treatments. VITA trial results demonstrated a 40.4% mean IOP reduction […]

Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatment

Avisi Receives FDA Approval to Study Novel Approach to Glaucoma Treatment

• Approved SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients. • VisiPlate® shunt is uniquely designed: novel metamaterial, thinner than a human hair, aiming for longevity, comfort, and aesthetics. • The multiple, redundant microchannels provide sustained aqueous flow while […]

Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society

REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ — Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Eydie Miller-Ellis, MD, as a Top Paper at the American […]

See All News